Phase III Study of Neoadjuvant TPF Chemotherapy Followed by Radiotherapy and Concurrent Nimotuzumab or Cisplatin for Locoregionally Advanced Nasopharyngeal Carcinoma (NPC).

Trial Profile

Phase III Study of Neoadjuvant TPF Chemotherapy Followed by Radiotherapy and Concurrent Nimotuzumab or Cisplatin for Locoregionally Advanced Nasopharyngeal Carcinoma (NPC).

Recruiting
Phase of Trial: Phase III

Latest Information Update: 03 Aug 2016

At a glance

  • Drugs Nimotuzumab (Primary) ; Cisplatin; Docetaxel; Fluorouracil
  • Indications Nasopharyngeal cancer
  • Focus Adverse reactions
  • Most Recent Events

    • 03 Aug 2016 New trial record
    • 07 Jun 2016 Results (n=155) presented at the 52nd Annual Meeting of the American Society of Clinical Oncology
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top